Another 🇳🇱 trial that makes absolute sense and funded by the government. We need more of these trials... Don't generate standing ovations, articles in the guardian or concomitant publications in NEJM. Just improve the way we take care of patients...

Much talk of BICR (blinded independent central review) ASCO. cf ascopubs.org/doi/10.1200/JC… "BICRs may introduce bias because of informative censoring, which results from having to censor unconfirmed locally determined progressions." i.e. tends to overstate PFS HT Ruth O'Regan

Always wonder why 'precision' in oncology is only about biology, when social determinants of health pay such a big role in patient outcomes. Screening them and minimizing their impact is paramount if we want treat patients besides treating their cancer. kudos to all of you :)

Don’t forget to register and submit an abstract for the ILC symposium! Deadline abstract submission= July 27. Looking forward to all seeing you there! ELBCC Patrick WB Derksen Philippe Aftimos, MD  Dr. Steffi Oesterreich Anne Vincent-Salomon European Lobular Breast Cancer Advocates Lobular Breast Cancer Alliance LobularBCUK GRASP Lobular Breast Cancer IRL #LivingWithLobular

My first ESMO MCBS Working Group meeting ESMO - Eur. Oncology Statistics, trial design and value brought to life ➡️ better outcome for #cancer patients What a dedicated and inspiring bunch of people ❤️

Unfortunately no OS benefit from Capivasertib in mTNBC w/ PIK3CA/PTEN/AKT1 alterations. We won't be giving current PIK3CA/AKTi in mTNBC. How to justify the agnostic prescription of these toxic drugs solely based on a PIK3CA/PTEN/AKT1 mut being identified? Alfredo Addeo MD Timothée Olivier, MD

Very happy that our study on socioeconomic inequalities in quality of life (QoL) for patients with early breast cancer (EBC) from the CANTO Study is finally out at Journal of Clinical Oncology. ascopubs.org/doi/10.1200/JC… 👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼 🔎Setting: • ~5900 women with EBC • Treated in multiple

New article in press: Impact of Hormone Receptor Status and Tumor Subtypes of Breast Cancer in Young BRCA Carriers Luca Arecco, MD; Eva Blondeaux; Matteo Lambertini, MD PhD doi.org/10.1016/j.anno…

JUST OUT in JAMA Oncology We look at all Adjuvant & Neoadjuvant drugs approved by FDA in last 5 years 43% of the time trials DON'T SAY what control arm pts get at relapse 75% of the time it is SUBOPTIMAL This means OS is *UNRELIABLE* Timothée Olivier, MD 🧵 drive.google.com/file/d/1cFt6Bt…

José Sandoval Journal of Clinical Oncology We would like to inform you that your post has been successfully published on @Oncodaily. Thank you for sharing! oncodaily.com/blog/89062.html

Here's the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (June 16th-23rd, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Latest Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center (👈 make sure to follow!)

I'm full of joy for having been interviewed by my friend and greatest scientist Khalid El Bairi for the The ASCO Post ! #Globaloncology #ONCOLLEGE #cancer 🗺️

Long-term outcomes by lobular vs ductal histology in four NSABP adjuvant BC trials 📌Patientts with ILC were older, had larger and more frequent ER-positive tumors, and more positive LN 📌Compared to NST (ductal) pts, those with ILC had a higher risk of late recurrence and

Mood of the day

Jaco, Bob Mintzer, Randy Brecker, Othello Molineux, Don Alias, Peter Erskine and Toots... youtu.be/7xWxHOoUXkg?si…

Fully agree with super MarleenKokLab: more ESMO - Eur. Oncology annual congresses in #Barcelona !!! #ESMO24 #ESMOAmbassadors OncoAlert Rebecca Dent

We were 9 strong at #ESMO24 from HUG, Oncology Division - Geneva University Hospital, Université de Genève& Timothée Olivier, MD virtually. Marie-E. Gaignard presented her work in the poster session, and Alfredo Addeo MD will be presenting the #ESMO24 lung cancer highlights on Tuesday. Looking forward to what the future holds!

Nous étions 9 à #ESMO24 des HUG Oncology Division - Geneva University Hospital Université de Genève & Timothée Olivier, MD virtuellement. Marie-E. Gaignard a présenté son travail lors de la session poster. Alfredo Addeo MD présentera les highlights sur le cancer du poumon mardi. Hâte de voir ce que l'avenir nous réserve!

Now speaking on the topic of #BreastcancerScreening and Implications for Invasive Lobular Carcinoma #ILC and requirement for risk adapted Screening including a protocol for Screening Women with #Densebreasts At #ILCSymposium Jose Sandoval José Sandoval 👏👏👏